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Epidemiological and experimental studies have re-
vealed an important role for prolactin (PRL) in breast
cancer. Cyclin D1 is a major downstream target of PRL
in lobuloalveolar development during pregnancy and is
amplified and/or overexpressed in many breast carci-
nomas. To examine the importance of cyclin D1 in PRL-
induced pathogenesis, we generated transgenic mice
(NRL-PRL) that overexpress PRL in mammary epithelial
cells, with wild-type, heterozygous, or genetically ab-
lated cyclin D1 in the FVB/N genetic background. Al-
though loss of one cyclin D1 allele did not affect PRL-
induced mammary lesions in nonparous females, the
complete absence of cyclin D1 (D1/) markedly de-
creased tumor incidence. Nevertheless, NRL-PRL/D1/
females developed significantly more preneoplastic le-
sions (eg, epithelial hyperplasias and mammary intra-
epithelial neoplasias) than D1/ females. Moreover,
although lack of cyclin D1 reduced proliferation ofmor-
phologically normal mammary epithelium, transgenic
PRL restored it to rates of wild-type females. PRL post-
transcriptionally increased nuclear cyclin D3 protein
in D1/ luminal cells, indicating one compensatory
mechanism. Consistently, pregnancy induced extensive
lobuloalveolar growth in the absence of cyclin D1. How-
ever, transcripts for milk proteins were reduced, and
pups failed to survive, suggesting that mammary differ-
entiation was inadequate. Together, these results indi-
cate that cyclin D1 is an important, but not essential,
mediator of PRL-induced mammary proliferation and
pathology in FVB/N mice and is critical for differentia-
tion and lactation. (Am J Pathol 2012, 181:294–302; http://
dx.doi.org/10.1016/j.ajpath.2012.03.041)
The hormone prolactin (PRL) is critical for mammary al-
veolar morphogenesis and differentiation.1 Recent epide-
294miological studies have also implicated PRL in the risk of
breast cancer, highlighting its importance in tumorigen-
esis. Elevated circulating PRL is associated with a higher
risk of development of tumors that express estrogen recep-
tor  (ER) and with poorer patient outcomes, and PRL
receptors (PRLR) are expressed at high levels in many
cancers.2,3 Moreover, particularly in women, the mammary
gland is exposed to locally produced PRL, in addition to that
from pituitary lactotrophs.4–6 Murine transgenic experimen-
tal models with elevated mammary PRL have demonstrated
the oncogenic potential of this hormone, and permit inves-
tigation of the mechanisms whereby PRL promotes breast
cancer development and progression.7
Epithelial proliferation is a key feature of PRL-driven
lobuloalveolar development during pregnancy,1 and the
cell cycle regulator, cyclin D1, has been reported to be a
critical mediator of this process.8 However, the role of
cyclin D1 in PRL-induced pathogenesis has not been
examined. The classic function of the D cyclins (D1, D2,
and D3) is promotion of the G1 to S phase of the cell
cycle, via regulation of their cyclin-dependent kinase
partners, CDK4 and CDK6.9,10 Activation of these kinases
by D cyclins results in phosphorylation of retinoblastoma
protein, leading to increased transcription of E2F-respon-
sive genes, and subsequent mitosis. In addition, cyclin D1
has been shown to regulate multiple other processes rele-
vant to oncogenesis, including other actions in cell cycle
progression, adhesion and migration, responses to DNA
damage, protein synthesis, metabolism, and differentiation,
in many cases, independently of CDK4/6 or its kinase ac-
tivity.11–14 The expression of individual D cyclins is tissue
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tissues.10 Mammary lobuloalveolar proliferation has ap-
peared to be an exception; genetic ablation of cyclin D1
(D1/) in the C57BL/6  129SV genetic background pre-
vented this event, culminating in lactation failure.15,16 This
phenotype is very similar to that observed in Prlr/ females
in the same mixed strain background.1
CCDN1 is amplified in a substantial subset of breast
carcinomas, and cyclin D1 protein is overexpressed in
many others (50% to 70%).13,17, 18 Many hormones and
growth factors, including PRL and estrogen, activate its
promoter.19 In MCF-7 breast cancer cells, PRL increases
transcription of cyclin D1,20 which is required for the
subsequent proliferative response.21 PRL also induces
nuclear accumulation of this cyclin in murine mammary
epithelial cells.22 The requirement for cyclin D1 in mam-
mary tumorigenesis secondary to well-characterized on-
cogenes has been investigated in murine models in the
C57BL/6  129SV genetic background. These experi-
ments demonstrated that cyclin D1 was essential for
some oncogenes, such as MMTV-driven neu (erbB2) and
v-Ha-ras, but also that the cyclin D1 status of mice ex-
pressingMyc (alias c-myc) andWnt-1 driven by the same
promoter did not affect tumor incidence or latency.23,24
Experimental models have demonstrated that aug-
mented proliferation also is an important contribution of
PRL to mammary tumorigenesis.25–28 To investigate the
requirement for cyclin D1 in PRL-induced pathology, we
used a murine transgenic model of elevated mammary
PRL, NRL-PRL. In this model, local PRL overexpression
driven by the estrogen- and PRL-independent promoter,
NRL, results in preneoplastic lesions, including epithelial
hyperplasias and mammary intraepithelial neoplasias,
similar to ductal carcinoma in situ in women, and eventu-
ally, invasive carcinomas, which resemble the clinical
luminal subtype.27,29 We generated NRL-PRL mice in the
context of genetic ablation of Ccdn1 in the FVB/N genetic
background. We found that cyclin D1 was important, but
not essential, for PRL-induced pathology. In nonparous
females without cyclin D1, transgenic PRL was able to
augment mammary epithelial proliferation, support alve-
olar development, and promote preneoplastic lesions
and tumors, albeit at a lower level than with wild-type
cyclin D1. PRL increased cyclin D3 expression posttran-
scriptionally, suggesting one compensatory mechanism.
Cyclin D1/ FVB/N females also displayed marked lobu-
loalveolar development during pregnancy, but expressed
reduced levels of milk protein transcripts. Together, these
observations indicate that cyclin D1 is not required for PRL-
initiatedmammogenic and tumorigenic signals in the FVB/N
genetic background. Understanding the mediators of PRL
actions in carcinogenesis will reveal potential sites for pre-
ventative and therapeutic interventions.
Materials and Methods
Reagents
5-Bromo-2-deoxyridine (BrdU) was purchased from Sigma-
Aldrich (St. Louis, MO), and 17-estradiol was obtainedfrom Steraloids (Newport, RI). Antibodies were pur-
chased from the following sources: BrdU (MAS-250) from
Accurate Scientific (Westbury, NY), estrogen receptor 
(ER; SC-542), cyclin D2 (SC-53637), cyclin D3 (SC-
182), and Grb2 (SC-255) from Santa Cruz Biotechnology
(Santa Cruz, CA); cyclin D1 (CP 236 B) from Biocare
Medical (Concord, CA), and rat anti-cytokeratin 8
(Troma1) from Developmental Studies Hybridoma Bank,
University of Iowa. Secondary antibodies, anti-rat and
anti-rabbit, were obtained from BioGenex (San Ramon,
CA) and signals detected with 3,3= diaminobenzidine
from Vector Laboratories (Burlingame, CA).
Mice
Cyclin D1 heterozygous mice that had been backcrossed
into the FVB/NJ strain (FVB.129S2(B6)-Ccnd1tm1Wbg/J)
were purchased from Jackson Laboratories (Bar Harbor,
ME). NRL-PRL mice [line 1647-13, TgN (Nrl-Prl)23EPS; line
1655, TgN(Nrl-Prl)24EPS] were generated and maintained
in the FVB/N strain as described.27 Offspring were geno-
typed for the PRL transgene and cyclin D1 using the prim-
ers shown in Table 1. All mice were housed and handled in
accordance with the Guide for Care and Use of Laboratory
Animals in Association for the Assessment and Accredita-
tion for Laboratory Animal Care–accredited facilities. All
procedures were approved by the University of Wisconsin–
Madison Institutional Animal Care and Use Committee.
17-Estradiol Treatment
For some experiments, Silastic pellets containing 20 g
of 17-estradiol were implanted subcutaneously in intact
female mice starting at 8 weeks of age, and replaced
every 6 weeks until the animal was euthanized at 1 year
of age. This dose has been shown to supplement circu-
Table 1. PCR Primers
Target Primer
Genetic manipulations
Prolactin transgene F, 5=-CCTCCTCATTCTCTGCTCTTC-3=
R, 5=-CCAATCACCCTTGCTCTAAACCC-3=
Cyclin D1 ablation 5=-TAGCAGAGAGCTACAGACTTCG-3=
5=-CTCCGTCTTGAGCATGGCTC-3=
5=-CTAGTGAGACGTGCTACTTC-3=
Real-time PCR
Cyclin D1 F, 5=-CGCCCTCCGTATCTTACTTCAA-3=
R, 5=-CTCACAGACCTCCAGCATCCA-3=
Cyclin D2 F, 5=-GCTCTGTGCGCTACCGACTT-3=
R, 5=-CCACGCTTCCAGTTGCAAT-3=
Cyclin D3 F, 5=-CGACTTCCTGGCCTTGATTC-3=
R, 5=-CAAAGGTGTAATCTGTAGCACAGA-3=
-Casein F, 5=-GCAGAAACTTCAGAAGGTGAATCTC-3=
R, 3=-TGACTGGATGCTGGAGTGAACT-3=
-Casein F, 5=-GGTCAACCTAAACCAGCAGAAAA-3=
R, 5=-TGTGCAACATTGGGAAAAGG-3=
Whey acidic protein F, 5=-CGCTCAGAACCTAGAGGAACAAG-3=
R, 5=-TGATACACTCTGTGCCCTCAATG-3=
Cytokeratin 8 F, 5=-TGAACAACAAGTTCGCCTCCTT-3=
R, 5=-TCCACTTGGTCTCCAGCATCT-3=
18S F, 5=-CGCCGCTAGAGGTGAATTTCT-3=R, 5=-CGAACCTCCGACTTTCGTTCT-3=
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trus.30 Uteri were weighed at the time of collection to
confirm the positive effect of the pellets. Uterine weight
did not differ in untreated mice and was significantly
increased in response to 17-estradiol in all genotypes
(see Supplemental Figure S1 at http://ajp.amjpathol.org).
Examination of Mammary Tissue
Histological assessments were performed on hematoxy-
lin and eosin–stained sections. Sections of some geno-
types and treatment groups were stained for BrdU, ER,
cyclin D1, and/or cyclin D3 (primary antibodies: BrdU,
1:40; ER, 1:1000; cyclin D1, 1:200; cyclin D3, 1:200),
and apoptosis was determined by morphological criteria
as described.27 The proportion of epithelial cells under-
going proliferation, apoptosis, and those expressing ER
and cyclin D3 was quantified in three to five mice of each
genotype by counting 2000 cells in at least 10 different
fields. One thousand cells from at least five distinct mi-
croscopic fields were counted in tumors to determine the
proportion of cells expressing detectable cyclin D1. For
gross evaluation of epithelial structures, mammary whole
mounts were prepared as described.27
Immunoblot Analysis
Western blot analyses of mammary homogenates were
performed as previously described28 Signals were quan-
tified by densitometry (ImageQuant software, v.4.2a; Mo-
lecular Dynamics, Sunnyvale, CA).
Real-Time PCR
RNA was isolated from mammary lysates using RNeasy Mini
Kit (Qiagen, Valencia, CA), and levels of transcripts deter-
mined by quantitative real-time PCR analysis as described
previously.31 The primers used are shown in Table 1.
Statistics
Statistical analyses were performed as described using
Prism version 4.03 (GraphPad Software, San Diego, CA).
Results
Absence of Cyclin D1 Reduces but Does
Not Prevent PRL-Induced Lesions and
PRL-Augmented Proliferation
In light of the association between PRL and cyclin D1 in
mammary epithelial proliferation revealed by several ex-
perimental approaches, we examined cyclin D1 expres-
sion in PRL-induced mammary carcinomas that devel-
oped in the context of wild-type cyclin D1. As shown in
Figure 1A, the proportion of cells expressing cyclin D1
correlated moderately positively with the rate of prolifer-
ation (Spearman r  0.5647; P  0.0004), consistent with
an important role for this cell cycle regulator in diverse,
established PRL-induced primary tumors.To evaluate the requirement for cyclin D1 in PRL-pro-
moted tumor development, we generated NRL-PRL mice
with wild-type, heterozygous, or genetically ablated cy-
clin D1 in the FVB/N genetic background. Nonparous
females of all genotypes were evaluated at 24 months of
age, when tumors reached 1.5 cm in diameter, or mice
developed significant health problems (end stage). As
shown in Figure 1B and Table 2, NRL-PRL females with
wild-type cyclin D1 developed palpable mammary tu-
mors with a high incidence, consistent with previous
studies.27 Heterozygosity for cyclin D1 did not alter the
incidence or latency of PRL-induced tumors. However,
ablation of cyclin D1 reduced the incidence to 12.5%,
and the latency tended to be longer than those with
wild-type cyclin D1 levels (P  0.0528, one-tailed Stu-
dent’s t-test). Interestingly, although tumors that arose in
NRL-PRL females with both or only a single cyclin D1
allele displayed varying histotypes (Table 2; Figure 2,
A–C), tumors that developed in NRL-PRL/D1/ females
were adenosquamous carcinomas.
Despite the paucity of carcinomas, transgenic PRL
A
B
Figure 1. A: Cyclin D1 expression correlates with the rate of proliferation in
PRL-induced tumors. A panel of diverse primary mammary tumors that
developed in NRL-PRL females in the presence of wild-type cyclin D1 was
examined by IHC for cyclin D1 and BrdU incorporation as described in
Materials and Methods (n  35; panel as described29). Each symbol repre-
sents a single tumor. The correlation coefficient was determined using Spear-
man’s nonparametric test (r 0.57; P 0.0004). B: The absence of cyclin D1
reduces the incidence and increases the latency of tumors in NRL-PRL fe-
males. Females of all genotypes were monitored until tumors reached 1.5 cm
in diameter, the mice developed significant health problems, or they reached
24 months of age (end stage). Absence of one cyclin D1 allele did not alter
the incidence or latency of PRL-induced tumors (P  0.83). However, loss of
both alleles significantly reduced tumor incidence (P 0.001), and tended to
increase tumor latency (P  0.0528, one-tailed Student’s t-test). Latencies
were compared using the Kaplan-Meier test, and differences between groups
were detected using the Mantel-Haenszel test.induced many preneoplastic lesions in the absence of
ed Stud
Prolactin Can Act Without Cyclin D1 297
AJP July 2012, Vol. 181, No. 1cyclin D1 that were readily apparent on histological ex-
amination (Figure 2, D–F, Table 3). NRL-PRL/D1/ fe-
males displayed significantly more epithelial hyperpla-
sias that were larger and more widespread than in
cyclin D1/ females (Table 3). Furthermore, although
mammary intraepithelial neoplasias were scarce in
D1/ mammary glands, they were readily apparent in
NRL-PRL/D1/ females. These data indicate that the
lack of D1 does not abrogate PRL-initiated pathogen-
esis, but rather suggest that it slows lesion progres-
sion. However, the limited healthy lifespan of these
mice precludes analysis of longer-term effects on tu-
mor development.
To better understand the underlying mechanism, the
rates of proliferation and apoptosis of morphologically nor-
mal mammary epithelium were determined. BrdU-labeled
Table 2. Effect of Cyclin D1 Status on Mammary Carcinogenesis
Genotype
Tumor incidence
at end stage*
Wild-type (FVB/N) 0/10 (0%)
NRL-PRL 8/1 8/11 (72.7%)†
Cyclin D1/ 0/7 (0%)
NRL-PRL/D1/ 9/11 (81.8%)
Cyclin D1/ 0/12 (0%)
NRL-PRL/D1/ 2/1 2/16 (12.5%)†
*End stage is defined as a tumor reaching 1.5-cm diameter in size or
†Incidences differ significantly (P  0.001, chi-square test).
‡Latencies trend toward a significant difference (P  0.0528, one-tail
A
E F G
  WT    PRL    D1-/-
CB
I J Kand ER-labeled epithelial cells were observed in ducts of
NRL-PRL/D1/ females (Figure 2, G and H, respectively).
Transgenic PRL increased both proliferation and apoptosis
in the presence of wild-type cyclin D1 compared to non-
transgenic females (Figure 3, A and B), as previously re-
ported.27,28 As expected, rates of proliferation were very
low in cyclin D1/ glands. However, PRL in the context of
cyclin D1 ablation was able to augment proliferation to lev-
els of nontransgenic glands (Figure 3A). The absence of
cyclin D1 significantly increased apoptosis, which strikingly
was reduced by transgenic PRL to wild-type levels (Figure
3B). This opposite net effect of transgenic PRL on apopto-
sis, depending on cyclin D1 status, suggests crosstalk be-
tween these factors in otherwise distinct pathways. Similar
patterns were observed in PRL-induced hyperplasias (Fig-
ure 3, A and B), although as expected,27 levels of prolifer-
parous Females
Tumor latency Tumor histotypes
ean  SD (months) (%)
N/A N/A
18.0  2.9‡ Adenocarcinomas:
Glandular (25)
Papillary (25)
Adenosquamous (12.5)
Carcinosarcomas (37.5)
N/A N/A
17.6  2.3 Adenocarcinomas:
Glandular (22.2)
Papillary (55.6)
Adenosquamous (22.2)
N/A N/A
22.1  2.4‡ Adenocarcinomas:
Adenosquamous (100)
s of age.
ent’s t-test).
  PRL/D1-/-
Figure 2. A–H: Diverse mammary carcinomas
and lesions develop in NRL-PRL and NRL-PRL/
D1/ females. A: Glandular adenocarcinoma
with eosinophilic secretions from an NRL-PRL
female. B: Papillary adenocarcinoma from an
NRL-PRL female. C: Adenosquamous carcinoma
from an NRL-PRL/D1/ female. D: Irregular
(degenerative) ductal epithelium and dilated
ducts in NRL-PRL/D1/ female. E: Mammary
intraepithelial neoplasia (MIN) within an epithe-
lial hyperplasia in NRL-PRL/D1/ female. F:
Epithelial hyperplasia in an NRL-PRL/D1/ fe-
male. G: BrdU-labeled epithelial cells in a duct
of an NRL-PRL/D1/ female. H: ER-labeled
epithelial cells in a duct of an NRL-PRL/D1/
female. I–L: Immunohistochemical localization
of cyclin D3 expression in mammary glands of
end-stage females. I: Wild-type (WT); J: NRL-
PRL; K: Cyclin D1/; L: NRL-PRL/D1/. Orig-
inal magnification:200 (A, C, D, E, F, and I–L);
100 (B); 400 (G and H).in Non
m
2 yearD
H
 L
5).
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normal structures. Together, these results indicate that cy-
clin D1 is not required for PRL-induced responses, but both
proliferation and neoplastic processes are facilitated by its
presence.
The ability of PRL to increase epithelial growth in the
absence of cyclin D1 was evident in mammary whole
mounts and histological sections from these end-stage
females. As expected from previous reports,15,16 wild-
type and cyclin D1/ glands displayed normal ductal
Table 3. PRL Increases Mammary Abnormalities in Cyclin D1/
Cyclin D1
Epithelial hyperplasias* 4/12†
Focal: 2/12
Multifocal:
Diffuse: 0/1
Mammary intraepithelial neoplasias 1/12†
Mammary glands were histologically examined at end stage.
Analysis performed by one-tailed chi-square test.
*Topographical distribution of hyperplasias as defined.32
†Indicates reduced frequency compared to NRL-PRL/D1/ (P  0.0
PRL D1-/- PRL/D1-/-WT
A
B
C
a
a
b b
a
a
b
b
c
a
a
b
Figure 3. A and B: Transgenic PRL induces proliferation of morphologically
normal ductal and hyperplastic epithelia in end-stage glands in the absence
of cyclin D1/ (A), and differently affects apoptosis depending on cyclin D1
status (B). Rates of proliferation and apoptosis were determined as described
in Materials and Methods. Data are expressed as the mean  SEM (n  3–5).
Analyses were performed by the Kruskal-Wallis test with the Mann–Whitney
posttest (P  0.05). Different letters (a, b, c) indicate statistically significant
differences among genotypes. C: NRL-PRL/D1/ females exhibit significant
lobuloalveolar development, albeit reduced compared to NRL-PRL females
with wild-type cyclin D1. Glands from all genotypes, including cyclin D1/,
displayed normal ductal development. Representative whole mounts at the
end stage of each genotype as indicated. Scale bar  2 mm. WT, wild type.development and branching, as well as some alveolar
budding, but developed alveoli were rare (Figure 3C). By
contrast, glands of NRL-PRL females with wild-type cy-
clin D1 exhibited many lobuloalveoli and hyperplasias, as
previously reported.27 Consistent with the ability of PRL to
augment proliferation in the absence of cyclin D1, trans-
genic PRL also induced limited lobuloalveolar develop-
ment in NRL-PRL/D1/ animals.
PRL Further Increases Cyclin D3 Expression in
the Absence of Cyclin D1
Although cyclin D2 and cyclin D3 can compensate for the
loss of cyclin D1 in many tissues,33 the lack of lobuloal-
veoli in pregnant C57BL/6  129SV cyclin D1/
mice15,16 suggested that the mammary gland may be an
exception. In light of the observed PRL-induced mam-
mary pathology in the absence of cyclin D1 in our study,
we examined the effect of elevated local PRL on expres-
sion of the other D cyclins. As shown in Figure 4, A–C,
mammary transcripts for both cyclin D2 and D3 were
increased in the absence of cyclin D1 as previously re-
ported.15,16 However, transgenic PRL did not further in-
crease these mRNAs. Analysis of protein expression,
however, revealed a more complex picture. PRL tended
to raise total mammary cyclin D2 and D3 protein levels in
D1/ glands, but not in those expressing wild-type levels
of cyclin D1 (Figure 4, D–F). Immunohistochemistry verified
the low levels of cyclin D3 in mammary glands with wild-
type cyclin D1 (Figures 2, I and J, and 4G), although it was
readily detectable in uteri of these individuals (see Supple-
mental Figure S2 at http://ajp.amjpathol.org). In glands of
D1/ females, cyclin D3 expression was clearly evident in
some epithelial as well as stromal cells (Figure 2K). Trans-
genic PRL strikingly elevated cyclin D3 protein levels in
D1/ glands, most notably in a subset of the cells lining the
lumens of the epithelial structures, indicating posttranscrip-
tional action (Figures 2L and 4G).
Cyclin D1/ Glands Exhibit Elevated ER
Expression, and Respond to 17-Estradiol
Supplementation and the Hormonal Milieu of
Pregnancy with Lobuloalveolar Development,
but Lactation Failure
To examine the effects of the absence of cyclin D1 on
s
NRL-PRL/D1/ NRL-PRL/D1/
11/16 11/11
Focal: 2/16 Focal: 0/11
Multifocal: 2/16 Multifocal: 0/11
Diffuse: 7/16 Diffuse 11/11
11/16 10/11Gland
/
2/12
2other indicators of hormonal responsiveness in the FVB/N
e expre
test, foll
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glands of age-matched 1-year-old nonparous females.
The absence of cyclin D1 elevated the proportion of cells
in normal mammary structures that expressed detectable
ER to levels comparable to those induced by transgenic
PRL in wild-type glands (Figure 5A), but this was not
further elevated by PRL. Increased numbers of ER
cells in D1/ glands may reflect the low proliferative
activity (Figure 3A); segregation of proliferation and ER
expression is observed in normal mammary tissue.34
Mammary epithelial structures in all genotypes re-
sponded readily to elevated systemic estrogen. Sup-
plementation with 17-estradiol beginning after ductal
elongation had occurred (8 weeks) elicited alveolar
budding when examined at 1 year of age regardless of
the presence of cyclin D1 (Figure 5, B and C). This
treatment also increased uterine weight, although to a
lesser extent in D1/ females, compared to those with
wild-type cyclin D1 (see Supplemental Figure S1 at
http://ajp.amjpathol.org).
Likewise, pregnancy induced extensive lobuloalveolar
development in nulliparous females of all genotypes.
Mammary glands of cyclin D1/ females were morpho-
logically similar to those with wild-type D1 at 24 hours
postpartum (Figure 6A). However, although apparently
healthy pups were born in comparably sized litters to
mothers of all genotypes, survival of pups born to cyclin
D1/ mothers regardless of transgenic PRL status
was dramatically reduced (Table 4). Although secre-
tions were apparent in alveolar lumens of D1/ moth-
ers, transcripts for milk proteins were significantly less
than those of mothers with wild-type D1, regardless of
transgenic PRL status (Figure 6, B–D). These data
indicate that mammary glands of FVB/N females are
E  Cyclin D2 protein               F  Cyclin D3 protein          G
D2 mRNA   A  Cyclin D1 mRNA  B  Cyclin C
a
a
b
a
a
b
b
b
Figure 4. Transgenic PRL does not further increase cyclin D2 and cyclin D3
of cyclin D1 (A), cyclin D2 (B), and cyclin D3 (C) were quantitated by RT-PCR
from individual end-stage mice for cyclin D1 (D1), cyclin D2 (D2), cyclin D
cyclin D3 (F) relative to keratin 8 levels from the Western blot analyses
immunohistochemistry (as described in Materials and Methods). E–G: Data ar
significant differences among genotypes, detected using the Kruskal-Wallisable to robustly proliferate in response to physiologicalcombinations of mammogenic hormones during preg-
nancy in the absence of cyclin D1. However, cyclin D1
itself is necessary for functional lactation, and compen-
satory mechanisms are not adequate.
thelial Cyclin D3  
D  Cyclin D1, D2, D3 protein  lin D3 mRNA
b c
a b
b c
a
b
c
n cyclin D1/ glands, but tends to increase cyclin D3 protein. mRNA levels
ibed inMaterials and Methods.D:Western blot analyses of mammary lysates
cytokeratin 8 (Krt8), and Grb2, as shown. Quantitation of cyclin D2 (E) and
: Proportion of epithelial cells that are positive for cyclin D3 protein by
ssed as the mean SEM (n 3). Different letters (a, b, c) indicate statistically
owed by the Mann–Whitney posttest (P  0.05). WT, wild type.
B Control
PRL D1-/- PRL/D1-/-
C 17β-estradiol-treated
PRL D1-/- PRL/D1-/-
WT
WT
A
* * *
Figure 5. A: ER is elevated in cyclin D1/ glands of 1-year-old nonparous
females. Morphologically normal epithelial cells expressing detectable ER by
IHC were quantified as described in Materials and Methods (mean SEM, n
5). *P  0.05 compared to WT. B and C: Nonparous females of all genotypes
respond to long-term 17-estradiol treatment with enhanced lobuloalveolar
development. Intact nonparous females of all genotypes were untreated (B), or
supplemented with 17-estradiol beginning at 8 weeks of age (C), and glands
were collected at 1 year of age (see Materials and Methods). Representative  Epi
  Cyc
a
a
mRNA i
as descr
3 (D3),
(D). Gwhole-mounted glands from each genotype as indicated. Scale bar 1mm.WT,
wild type.
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Cyclin D1 is a physiological mediator of lobuloalveolar
proliferation induced by PRL and cooperating hormones
during pregnancy.35 Using a transgenic model of ele-
vated local PRL exposure in combination with germline
deletion of Ccnd1 in the FVB/N genetic background, we
demonstrated herein that cyclin D1 is also required for
maximal PRL-promoted mammary tumorigenesis. How-
ever, even in the absence of cyclin D1, transgenic PRL
increased mammary epithelial proliferation, induced
early lesions, and promoted carcinomas, albeit with a
reduced incidence and longer latency. PRL posttran-
scriptionally increased epithelial cyclin D3 expression,
revealing one underlying compensatory mechanism.
Mammary epithelium of cyclin D1–deficient females also
proliferated in response to other hormones, including
supplemental estrogen and the complex endocrine mi-
lieu of pregnancy. Nonetheless, despite extensive lobu-
loalveolar development during gestation, pups failed to
survive due to apparent lactational failure. Together, our
data indicate that compensatory mechanisms, including
cyclin D3, are able to partially replace cyclin D1 in PRL-
induced proliferation, but cannot compensate for cyclin
D1 in PRL-induced differentiation. These studies point to
distinct actions of cyclin D1 in hormonal regulation of
mammary function, as well as genetic differences among
mouse strains.
Circulating PRL is associated primarily with ER
breast cancer,3 modeled by experimental PRL-induced
carcinomas.29 The significant correlation between prolif-
eration and cyclin D1 expression in the tumors that de-
velop in NRL-PRL females shown here is consistent with
the observed high cyclin D1 expression in ER clinical
A B C DWT PRL D1-/- PRL/D1-/-
A
γ
B  C  D  
β casein/ keratin 8 mRNA      casein/ keratin 8 mRNA      WAP/ keratin 8 mRNA
a
a b
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a a
b b
a
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Figure 6. Cyclin D1 status does not affect mammary development during
pregnancy, but is essential for optimal milk protein synthesis. Nulliparous
females of the different genotypes were bred to wild-type FVB/N males, and
pup health and mammary morphology were assessed 24 hours after partu-
rition. A: Mammary glands at day 1 postpartum of each genotype as indi-
cated. Original magnification, 100. B–D: Mammary glands of cyclin D1/
mothers contain lower levels of transcripts for milk proteins  casein (B),
 casein (C), and WAP (D) compared to cytokeratin 8, regardless of PRL
transgene status. Levels of specific RNAs in mammary lysates from mothers of
different genotypes were determined by real-time PCR as described in Ma-
terials and Methods (mean  SD, n  3 to 5). Different letters (a, b, c)
indicate statistically significant differences among genotypes by analysis of
variance followed by the Tukey Multiple Comparison test (P  0.05).tumors.11,13 PRL increases expression of cyclin D1 viatranscription,20 as well as nuclear accumulation and sta-
bilization of the protein.22 Although mammary transcripts
for both cyclin D2 and D3 were elevated in D1/ FVB/N
females in the current study, similar to reports in other
genetic backgrounds,15,16 PRL did not further increase
levels of these mRNAs. The apparent lack of PRL-stimu-
lated transcription of these other D cyclins in the mam-
mary gland in vivo suggests that regulatory signals to
these genes are cell specific; Stat5, a prominent mediator
of PRL in the mammary gland,36 mediates activation of
both the cyclin D2 and D3 promoters in response to other
cytokines in other cell types.37,38 However, our studies
showed that PRL increased cyclin D3 protein in luminal
epithelial cells of NRL-PRL/D1/ females. Nuclear ac-
cumulation of cyclin D3, like cyclin D1, is regulated by
glycogen synthase kinase-3–dependent phosphoryla-
tion, subsequent nuclear export and proteasomal degra-
dation,39,40 a pathway inhibited by PRL in mammary
epithelium.22 This mechanism is likely to contribute to the
ability of PRL to induce the mammary epithelial prolifer-
ation and pathology in the absence of cyclin D1 observed
in our studies. In light of the incomplete compensation
observed in our study, it is interesting to note that cyclin
D3 was less effective than cyclin D1 in stimulating mitosis
of hepatocytes.41
The role of cyclin D3 in breast cancer is less studied
than that of cyclin D1. Cyclin D3 is elevated in some
clinical breast cancers, frequently in conjunction with cy-
clin D1.42–44 Experimental overexpression of cyclin D3
results in squamous cell carcinomas in mice,45 demon-
strating that this D cyclin also can contribute to mammary
oncogenesis. In addition, cyclin D3 may confer distinct
phenotypic features to mammary cancers. Like those
tumors that developed in MMTV-cyclin D3 mice, both of
the carcinomas that developed in NRL-PRL/D1/ fe-
males exhibited a squamous histotype. This phenotype
contrasts with the adenocarcinomas that develop in
MMTV-cyclin D1 females,46 suggesting distinct actions of
different D cyclins on either a subpopulation of epithelial
cells or cellular functions. Indeed, limited studies have
demonstrated that cyclin D family members determine
different substrates of activated CDK4/6,47 and associate
with distinct transcriptional regulators in breast cancer
cells in vitro (see below).
In addition to effects on D cyclins, PRL alters expres-
sion of the cell cycle regulators p21Cip/WAF1 and cyclin
Table 4. Pups of cyclin D1/ Mothers Exhibit Poor Survival
Genotype
Litter size at
birth
Pup survival
(%)
Mean  s.d. Mean  s.d.
Wild type (FVB/N) n  5 7.4  1.5 84.0  12.1
NRL-PRL n  4 9.0  1.1 86.9  12.5
Cyclin D1/ n  7 7.0  1.4 21.1  17.7*
NRL-PRL/D1/ n  9 7.0  1.4 35.7  43.0
Nulliparous females of all genotypes were bred to nontransgenic
males. Litter size was observed on PND 0 and survival on PND 1, when
tissues were collected for analysis.
Analysis performed by Student’s t-test.
*Indicates reduced frequency compared to wild-type and NRL-PRL
mice.
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plemented by direct and indirect actions of other hor-
mones in the complex environment of pregnancy, are
likely to contribute to the extensive lobuloalveolar devel-
opment in D1/ periparturient females observed here.
Compensation for the loss of cyclin D1 in lobuloalveo-
lar growth was not evident in the first descriptions of cyclin
D1/ mice, which were carried out in the C57BL/6 
129SV genetic background.15,16 However, in addition to
our study, Wagner and colleagues43 also recently re-
ported reduced mammary cyclin D1 dependence in the
FVB/N strain, and Haslam and colleagues48 reported ex-
tensive alveologenesis during pregnancy in BALB/c
D1/ females. Together, these studies suggest that the
original strain background, which is known to display
reduced hormonal responsiveness,48,49 may be unusual
in this aspect. These reports underscore the importance
of genetic background, which needs to be taken into
account because mouse models are used to dissect
complex biological processes, such as oncogenesis.
This is particularly critical in light of the role of cyclins in
hormonal actions in breast cancer,13 and the potential
role of cyclin D1 in tumor progenitor populations.23,24,50
Strain differences also present the opportunity to identify
the genetic loci that dictate the distinct phenotypes;
these studies also may elucidate factors underlying sus-
ceptibility and resistance to breast cancer in women.
In contrast to the ability of compensatory mechanisms
to support proliferation and support marked lobuloalveo-
lar development in the absence of cyclin D1 in both
FVB/N as well BALB/c females, pups failed to survive,
indicating that cyclin D1 itself is essential for lactational
competence. The reduced transcripts for milk proteins in
D1/ mammary glands shown here indicate that this
may result from incomplete differentiation rather than in-
adequate alveolar capacity. Using a “knocked-in” cyclin
D1 mutant that is unable to activate CDK4/6, Landis and
colleagues51 demonstrated that lobuloalveolar develop-
ment is independent of kinase activity. Cyclin D family
members have been shown to exert kinase-independent
actions on transcription via multiple mechanisms in a
variety of systems.11,13,14 An elegant study examining
cyclin D1–associated proteins in mouse embryos deter-
mined that about one third of the identified proteins were
transcription factors.52 Our data suggest that these ac-
tions may be less readily compensated in the mammary
gland. In support of this, Mullany and colleagues41 found
that substantial subsets of transcripts were distinct in
hepatocytes overexpressing individual D cyclins. Indeed,
cyclin D1 is a strikingly stronger activator of the transcrip-
tional activity of ER than either D2 or D3.53,54 Additional
study will be required to dissect the specific targets of
individual D cyclins in the mammary gland and genetic
modulation of these responses.
In light of the accumulating evidence implicating PRL
in the development and progression of ER tumors3
and increased expression of cyclin D1 in early lesions
and carcinomas, especially luminal tumors,11,13,17 it is
important to understand the relationship between these
factors in breast cancer. Our studies here demonstrate
the importance of cyclin D1 in PRL-induced mammaryproliferation and pathogenesis, but also reveal other me-
diators likely to include cyclin D3 in the murine FVB/N
genetic background. Understanding the web of signals
that generate the array of phenotypes and variation in
therapeutic responsiveness of the luminal subtype of
breast cancer will illuminate strategies to prevent and
treat this disease.
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